Cited by 62Sirtuins and Resveratrol in MedicineInflammasome and immune disordersSARS-CoV-2 and COVID-19 Research

NAD+ in COVID-19 and viral infections

Open access
Zheng, Minyan, Schultz, Michael B., Sinclair, David A.·2022·Trends in Immunology

Abstract

NAD+, as an emerging regulator of immune responses during viral infections, may be a promising therapeutic target for coronavirus disease 2019 (COVID-19). In this Opinion, we suggest that interventions that boost NAD+ levels might promote antiviral defense and suppress uncontrolled inflammation. We discuss the association between low NAD+ concentrations and risk factors for poor COVID-19 outcomes, including aging and common comorbidities. Mechanistically, we outline how viral infections can further deplete NAD+ and its roles in antiviral defense and inflammation. We also describe how coronaviruses can subvert NAD+-mediated actions via genes that remove NAD+ modifications and activate the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Finally, we explore ongoing approaches to boost NAD+ concentrations in the clinic to putatively increase antiviral responses while curtailing hyperinflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.it.2022.02.001

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zheng, M., Schultz, M. B., & Sinclair, D. A.
Affiliations
Harvard University (US)
Corresponding author
Sinclair, David A.
Venue
Trends in Immunology
Publisher
Elsevier BV
Published
2022-04
Volume
43
Issue
4
Pages
283-295
ISSN
1471-4906 (ISSN-L)
OpenAlex
W4211221655
Cited by
62
References
117
Citations by year
2026: 9 · 2025: 13 · 2024: 16 · 2023: 16 · 2022: 8
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • Trends in Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
NAD+, COVID-19 pandemic, SARS-CoV-2, viral infection, antiviral immunity, inflammation, hyperinflammation, NLRP3 inflammasome, aging, comorbidities, NAD+ supplementation
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, COVID-19, Humans, NAD, Virus Diseases, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review